QLGNQualigen Therapeutics, Inc.

Nasdaq qualigeninc.com


$ 0.28 $ 0.00 (1.14 %)    

Thursday, 09-May-2024 15:47:17 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 0.2834
$ 0.28
$ 0.30 x 100
$ 0.00 x 0
$ 0.28 - $ 0.28
$ 0.27 - $ 1.26
86,167
na
1.44M
$ -0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-08-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 05-02-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 11-12-2020 09-30-2020 10-Q
14 08-14-2020 06-30-2020 10-Q
15 05-01-2020 03-31-2020 10-Q
16 03-31-2020 12-31-2019 10-K
17 11-14-2019 09-30-2019 10-Q
18 08-14-2019 06-30-2019 10-Q
19 05-15-2019 03-31-2019 10-Q
20 04-01-2019 12-31-2018 10-K
21 11-09-2018 09-30-2018 10-Q
22 08-14-2018 06-30-2018 10-Q
23 05-15-2018 03-31-2018 10-Q
24 03-19-2018 12-31-2017 10-K
25 10-31-2017 09-30-2017 10-Q
26 08-07-2017 06-30-2017 10-Q
27 05-09-2017 03-31-2017 10-Q
28 02-27-2017 12-31-2016 10-K
29 11-07-2016 09-30-2016 10-Q
30 08-08-2016 06-30-2016 10-Q
31 05-09-2016 03-31-2016 10-Q
32 03-21-2016 12-31-2015 10-K
33 11-10-2015 09-30-2015 10-Q
34 08-12-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 qualigen-therapeutics-novel-direct-pan-ras-inhibitors-presented-at-american-association-of-cancer-research-2024-annual-meeting

Poster Includes Preclinical Data on Novel Direct Pan-RAS InhibitorsCARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualige...

 qualigen-therapeutics-new-publication-released-in-the-nature-scientific-reports-journal-titled-structureactivity-relationships-for-the-g-quadruplex-targeting-experimental-drug-qn-302-and-two-analogues-probed-with-comparative-transcriptome-profiling-and-molecular-modeling

https://www.nature.com/articles/s41598-024-54080-2

 why-richardson-electronics-shares-are-trading-lower-by-13-here-are-20-stocks-moving-premarket

Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted wea...

 qualigen-therapeutics-provides-corporate-update-for-q3-and-to-date-2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic ...

 qualigen-therapeutics-announces-first-patient-dosed-in-the-phase-1a-clinical-trial-of-qn-302-for-treatment-of-advanced-or-metastatic-solid-tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and...

 qualigen-therapeutics-partners-with-td2-for-phase-1-clinical-development-of-qn-302-for-the-treatment-of-advanced-or-metastatic-solid-tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and...

 qualigen-therapeutics-q2-eps-069-up-from-110-yoy-sales-163m-up-from-143m-yoy

Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.69) per share. This is a 37.27 percent increase over losse...

 qualigen-therapeutics-announces-us-fda-ind-clearance-to-initiate-phase-1-clinical-trial-of-qn-302-for-treatment-of-advanced-or-metastatic-solid-tumors

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demon...

 qualigen-therapeutics-divests-fastpack-diagnostics-business

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen'...

 qualigen-therapeutics-highlights-poster-presentation-for-pan-ras-inhibitor-platform-at-2023-asco-meeting

Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds

 qualigen-therapeutics-q1-eps-078-up-from-120-yoy-sales-161m-miss-200m-estimate

Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.78) per share. This is a 35 percent increase over losses o...

 watching-qualigen-therapeutics-zacks-small-cap-research-sets-5-price-valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_05122023_QLGN_Bautz.pdf

 qualigen-therapeutics-presents-data-on-qn-247-in-triple-negative-breast-cancer-at-the-american-association-for-cancer-research-aacr-annual-meeting-in-orlando

Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 81 companies hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-monday

  On Monday, 89 stocks made new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION